Uncovering the Mystery: What is Livagen?
Livagen is a revolutionary peptide supplement, specifically designed to boost liver function and overall health.
Through the modulation of the pineal gland’s activity, Epitalon promotes more efficient functioning of the body’s physiological processes. These include the liver’s detoxification pathways, which are significantly enhanced with regular intake of Livagen. Consequently, this leads to an improved antioxidative defense, preventing cellular damage and improving overall health.
Livagen: A Deep Dive into its Mechanism
By harnessing the power of Epitalon, Livagen works at a cellular level to protect the liver from damage. It mitigates the harmful effects of toxins and oxidative stress, which are primary factors responsible for liver dysfunction.
Livagen operates in a two-pronged approach. It boosts the liver’s natural detoxification processes while promoting the regeneration of liver cells. This dual action not only enhances liver health but also aids in the overall wellbeing of the individual.
The Advantages of Livagen: The Liver and Beyond
Livagen’s influence on liver health cannot be overstated. By increasing the liver’s natural antioxidative defenses, it provides a robust shield against various harmful toxins that are omnipresent in modern life.
Our liver is the primary detoxification organ in our bodies. It neutralizes harmful toxins that would otherwise accumulate and lead to various health complications. Livagen enhances the liver’s function, ensuring these toxins are neutralized more efficiently.
Furthermore, by promoting the regeneration of liver cells, it ensures the liver can continuously perform its essential functions without being degraded over time. This leads to improved liver health, culminating in a healthier body and an enhanced quality of life.
Livagen’s benefits extend beyond merely supporting liver health. It is a powerful ally in the quest for a healthier, more vibrant life. Here are the key advantages of Livagen that make it a superior choice:
As a derivative of Epitalon, Livagen exhibits potent anti-aging properties. It helps slow down the aging process, promoting a longer, healthier life.
Enhanced Energy Levels and Lifespan
By improving liver function, Livagen assists in enhancing overall energy levels. Aside from improving immunity, Livagen also has a significant impact on lifespan
The Power of Livagen: Proven by Continued Research
It’s not just hearsay. The power of Livagen has been solidly backed up by a plethora of scientific research. Several studies have proven the effects of Livagen, with results showing a marked increase in liver function, vitality, and overall health.
Below are some findings from a number of past researches been done by renowned peptides researchers on Livagen:
Livagen and the Immune System
DNA is contained within the nucleus of eukaryotes, like humans, in a hierarchy of ever more condensed organization that takes the roughly 3 feet of DNA that is contained within a human cell and packages it to fit within the space of one hundredth of a millimeter. In other words, the packaging of DNA reduces its overall size by about 100,000 times. The double helix of DNA is wrapped around proteins, called histones, which themselves conglomerate to form chromatin structure, which further condenses to form chromosomes. This progressive organization of DNA serves several purposes including condensing the genetic material for replication and cell division, condensing the genetic material so that it fits within cells, and controlling expression of genes at a very high level. In other words, DNA organization is all about packaging the genetic material and about controlling access to specific genes.
The latter function of chromatin, controlling gene expression, Research in older adults suggests that Livagen activates a number of genes in the lymphocytes of older people by inducing the decondensation (unpacking) of chromatin. This results in the activation of genes that are otherwise silent in older adults including ribosomal genes responsible, indirectly, for robust protein production and enhanced cell activity. This information suggests that Livagen has a direct effect on the DNA within lymphocytes, which are a primary cell of the immune system.
Research looking that the endpoints of Livagen, Epitalon, and Vilon administration in elderly individuals shows that Livagen has four different effects in lymphocytes including
- activating synthetic processes by reactivating ribosomal genes,
- unpacking chromatin,
- altering gene expression, and
- inducing decondensation.
All these effects lead to reactivation of chromatin that is silenced as we age. Though long-term effects have not been studied, there is the belief among researchers that this resets lymphocytes to a more “youthful” state.
Lymphocytes are a class of white blood cell that contains B cells and T cells. B cells produce antibodies against foreign invaders while T cells destroy cells of the body that are either infected with an invading organism or have become cancerous. T cells also produce cytokines, which are chemical signals that coordinate immune responses and control inflammation in the body. In other words, lymphocytes are among the most important cells of the immune system. Their decline in activity with age may be at least part of the explanation for why we become more susceptible to all varieties of disease and illness as we age. The ability to reset these cells to a more youthful state could help to ward off infection and cancer.
Livagen and the Heart
Lymphocytes play an active role in cardiac health, so it was natural for researchers to wonder what effects Livagen might have on the heart. Research in patients with hypertrophic cardiomyopathy (HCM) suggests that dysregulation of chromatin structure in lymphocytes is a pathogenic feature in HCM and atherosclerosis that, if correct, may improve long-term outcomes.
Several studies suggest that release of genes via decondensation of chromatin in lymphocytes may help to reduce long-term sequelae from various forms of heart disease. Of course, this is precisely what Livagen does and so there has been a great deal of research in this area, . Changes to lymphocyte gene expression may help to reduce inflammation and the scarring that it leads to in individuals with HCM. Livagen may also be useful for preventing the onset of HCM in those who are genetically predisposed to the condition as well as following heart attack or other cardiac injury. Livagen may provide the basis for advanced preventative strategies that will reduce the overall morbidity and mortality associated with heart disease.
Enkephalins are short peptides that the body uses to signal pain. They bind to both mu and delta opioid receptors. Mu receptors, which bind morphine, cause a reduction in pain, blood pressure, and consciousness when activated. Delta receptor activation leads to reduced pain perception and may account for the respiratory depression seen with opiates. Work on bioregulatory peptides shows that Livagen inhibits the activity of enkephalin-degrading enzymes in the blood, thereby increasing levels of natural pain killers in the body. Naturally, this suggests that Livagen may be an effective treatment for pain. There is ongoing research to determine how well it controls pain, what the side effects of enhanced enkephalin levels are, and whether there is any addictive potential as there is with opioids like Oxycontin.
Livagen and the GI Tract
New research suggests that both my and delta receptors, when activated, play an important role in protecting the mucosal barrier of the GI tract. The net result of Livagen in this setting is an increase vagal nerve signaling to the GI tract and altered levels of both mucosal nitric oxide and prostaglandins. This leads to profound gastroprotection that may be useful in everything from treating infectious diarrhea to reducing the symptoms and long-term consequences of inflammatory bowel disease. Given its ability to enhanced activation of these receptors by enhancing levels of enkephalin in the bloodstream, it should come as no surprise that Livagen is being considered as a potential treatment for a variety of disorders of the GI tract.
Livagen and Aging
What should be obvious by now is that many of the effects of aging are a result of changes in the way DNA is organized and thus the types of genes that can be accessed and expressed. These changes have been detailed in research by the leading authority on chromatin changes in aging, Professor Teimuraz Lezhava. His work shows that levels chromosomal aberrations increase with age. These aberrations include progressive condensation of chromatin (think of this as increasing inactivation of DNA) and decreases in repair processes (secondary to the inactivation that arises from condensation). There is good evidence to suggest that reversing the process of condensation may, in fact, be an effective means of extending lifespan. After all, if silencing genes leads to progressively faster aging, reactivating those genes should slow the process. Dr. Lezhavas’s research shows that Livagen, Epitalon, and a handful of other bioregulatory peptides are already know to impact this process by decondensing DNA. His work shows that there is good reason to believe that these peptides can, in fact, help to thwart some of the dysfunction that arises with age, particularly as it relates to immune dysregulation and decreased protein synthesis.
Livagen is a short bioregulatory peptide that has direct effects on DNA structure and function. It is best known for its ability to decondense chromatin, thereby increasing the expression of certain genes and improving the “youthful” profile of cells. Its most studied effects are on lymphocytes of the immune system. Through these cells, Livagen helps to activate the immune system and offset disease in the heart, GI tract, immune system, and central nervous system. Livagen even shows promise in the area of nociception and pain control. Ongoing research will help to further unravel the promise of Livagen and bring humanity closer to understanding the processes of aging and senescence.
The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Scientific Journal Author
Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of genome peptide regulation” (Karger AG, 2005). Vladimir Khavinson introduced scientific specialty “Gerontology and Geriatrics” in the Russian Federation on the governmental level. Academic Council headed by V. Khavinson has oversighted over 200 Ph.D. and Doctorate theses from many different countries.
Prof. Vladimir Khavinson is being referenced as one of the leading scientists involved in the research and development of Livagen. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between PeptidesforSale.com and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Prof. Vladimir Khavinson is listed in   and  under the referenced citations
References and Citations
 “Chromatin,” Genome.gov. https://www.genome.gov/geneticsglossary/Chromatin (accessed Feb. 05, 2022).
 V. Kh. Khavinson et al., “Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People,” Bull. Exp. Biol. Med., vol.134, no. 4, pp. 389–392, Oct. 2002, doi: 10.1023/A:1021924702103.
 T. Lezhava, J. Monaselidze, T. Kadotani, N. Dvalishvili, and T. Buadze, “Anti-aging peptide bioregulators induce reactivation of chromatin,” Georgian Med. News, no. 133, pp. 111–115, Apr. 2006.
 “Lymphocyte,” Genome.gov. https://www.genome.gov/geneticsglossary/Lymphocyte (accessed Feb. 05, 2022).
 T. A. Dzhokhadze, T. Z. Buadze, M. N. Gaiozishvili, N. G. Kakauridze, and T. A. Lezhava, “[Genomic instability in atherosclerosis],” Georgian Med. News, no. 236, pp. 82–86, Nov. 2014.
 T. Lezhava and T. Jokhadze, “Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals,” Ann. N. Y. Acad. Sci., vol. 1100, pp. 387–399, Apr. 2007, doi: 10.1196/annals.1395.043.
 “[Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives],” Georgian Med. News, no. 234, pp. 134–137, Sep. 2014.
 T. A. Dzhokhadze, T. Z. Buadze, M. N. GaÄozishvili, A. Rogava, and T. A. Lazhava, “[Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and Syn-Coll relatives)],” Georgian Med. News, no. 225, pp. 94–97, Dec. 2013.
 N. V. Kost, O. I. Sokolov, M. V. Gabaeva, I. A. Zolotarev, V. V. Malinin, and V. K. Khavinson, “[Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum],” Izv. Akad. Nauk. Ser. Biol., no. 4, pp. 427–429, Aug. 2003.
 K. Gyires and A. Z. Rónai, “Supraspinal delta- and mu-opioid receptors mediate gastric mucosal protection in the rat,” J. Pharmacol. Exp. Ther., vol. 297, no. 3, pp. 1010–1015, Jun. 2001.
 T. A. Lezhava, “[Human chromosome functional characteristics and aging],” Adv. Gerontol. Uspekhi Gerontol., vol. 8, pp. 34–43, 2001.
 V. K. Khavinson et al., “Peptide Epitalon activates chromatin at the old age,” Neuro Endocrinol. Lett., vol. 24, no. 5, pp. 329–333, Oct. 2003.